John A. Glaspy, MD, MPH
John Glaspy, MD, MPH, is professor of medicine in the Department of Medicine, Division of Hematology/Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. Glaspy serves as co-chair to the division with Dr. Dennis Slamon. Dr. Glaspy holds the Estelle, Abe, and Marjorie Sanders Endowed Chair in Cancer Research. He is director of the JCCC Clinical Research Unit and director of the JCCC Women’s Cancer Research Program. He is a researcher and oncologist with a national reputation in clinical medicine as an acute diagnostician and outstanding clinician.
Dr. Glaspy is a member of the American Society of Clinical Oncology, Southwest Oncology Group, American Federation for Clinical Research, International Society of Interferon Research, and American Society of Nuclear Medicine, among others. He is also a fellow of the American College of Physicians. During the course of his career, Dr. Glaspy has authored more than 270 articles, abstracts, and book chapters. He has received numerous awards and honors, including being named one of the “Best Doctors in America.”
Currently, Dr. Glaspy is involved in basic research in tumor immunology and the effects of fatty acids on carcinogenesis. His clinical interests also include chemotherapy-induced anemia, the role of hematopoietic growth factors in cancer management, and new approaches to the treatment of breast cancer and malignant melanoma. Dr. Glaspy received his MD from the UCLA School of Medicine and his MPH in health services administration from the UCLA School of Public Health. He completed his residency in internal medicine and his fellowship in hematology and oncology at the UCLA School of Medicine.
Dr. Glaspy understands the value of providing integrative care to patients with cancer and has been a strong advocate for these services. He is devoted to providing the leadership from the Department of Medicine on the Founders Board because of his strong belief in the mission of the Simms/Mann Center. He considers the Simms/Mann Center to be an essential part of comprehensive oncology care.